Central Nervous System News and Research

RSS

OptiNose's bi-directional nasal device delivering fluticasone effective in reducing nasal polyps in CRS patients

OptiNose Inc. announced today that a subgroup analysis of positive Phase II trial results has been published in the July/August issue of the American Journal of Rhinology & Allergy.

11 Aug 2010

AACN endorses new clinical practice guidelines developed by Renal Physicians Association

The American Association of Critical-Care Nurses (AACN) recently endorsed the clinical practice guideline, "Shared Decision Making in the Appropriate Initiation of and Withdrawal from Dialysis," developed by Renal Physicians Association (RPA), Rockville, Md.

11 Aug 2010

Trigemina reports positive results from TI-001 Phase IIa clinical trial for Chronic Daily Headache

Trigemina, Inc., a Mountain View, CA based pharmaceutical company, reports positive results from its Phase IIa proof-of-concept clinical trial for TI-001 in Chronic Daily Headache. The trial is a collaborative effort between Trigemina and Dr. Egilius Spierings of MedVadis Research Corporation located outside of Boston, and compares intranasal TI-001 with placebo in patients suffering from CDH.

11 Aug 2010

Georgia Institute receives EUREKA grant to design brain tumor treatment

The Georgia Institute of Technology has received a EUREKA grant from the National Institutes of Health (NIH) to design a new way to treat invasive brain tumors by capturing the migrating cells that spread the disease. The EUREKA -- Exceptional, Unconventional Research Enabling Knowledge Acceleration -- program helps scientists test new, unconventional ideas or tackle major methodological or technical challenges.

11 Aug 2010

Omeros net loss for second-quarter 2010 increases to $7.8 million

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced financial results for the three and six months ended June 30, 2010.

11 Aug 2010

China Pharma second-quarter revenue increases 22% to $16.6 million

China Pharma Holdings, Inc., a leading fully-integrated specialty pharmaceuticals company in China, today announced financial results for the second quarter ended June 30, 2010.

10 Aug 2010

ACADIA second-quarter net loss decreases to $4.3 million

ACADIA Pharmaceuticals Inc., a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today reported its unaudited financial results for the second quarter ended June 30, 2010.

10 Aug 2010

Scientists induce nerve tissue regeneration in patients with spinal cord injury

Researchers for the first time have induced robust regeneration of nerve tissue connections in injured adult spinal cord sites that control voluntary movement. These findings provide hope that it may be possible to design therapies for paralysis and other impairments of motor function arising from spinal cord injury.

9 Aug 2010

Need for trained medical professionals to treat medical emergencies in high school athletes

As summer football practice gets into full swing, it's essential to be aware of the risk of exertional heat stroke (EHS) in high school athletes, according to a Safety Alert in The Journal of Strength and Conditioning Research, official research journal of the National Strength and Conditioning Association. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals, and institutions in medicine, nursing, allied health, and pharmacy.

6 Aug 2010

Biovail second-quarter total revenues increase 23% to $238.8 million

Biovail Corporation today announced financial results for the three-month and six-month periods ended June 30, 2010.

5 Aug 2010

Life Technologies, UCSD Moores Cancer Center to use SOLiD 4 technology to study CLL

Life Technologies Corporation and the University of California at San Diego Moores Cancer Center today announced a partnership to use SOLiD 4 genomic analysis technology in a research program to study chronic lymphocytic leukemia, a cancer of the white blood cells. The CLL research is made possible by funding from the National Institutes of Health and will enable scientists to survey the whole transcriptomes of 96 CLL tumor samples for potential biomarkers.

5 Aug 2010

Vanda second-quarter 2010 revenues decrease by $4.1M

Vanda Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced financial and operational results for the second quarter and six months ended June 30, 2010.

5 Aug 2010

BioClinica second-quarter service revenues increase to $15.7 million

BioClinica, Inc., a global provider of clinical trial management services, today announced its financial results for the second quarter and six months ended June 30, 2010.

From Clario 4 Aug 2010

Research shows no link between CCSVI and development of multiple sclerosis

Two important new studies challenge the controversial hypothesis that venous congestion—chronic cerebrospinal venous insufficiency (CCSVI)—contributes to the development of multiple sclerosis (MS). This theory has resulted in many MS patients receiving experimental endovascular angioplasty, a treatment for MS unproven by clinical trials.

2 Aug 2010

Measuring GAPDH inhibiting antibodies can result in long-term treatment for MS

UCI immunologists have found that testing for increased levels of antibodies that inhibit energy production in neurons can detect axon and neuron degeneration in multiple sclerosis earlier than existing diagnostic tools.

31 Jul 2010

FDA lifts hold, allows Geron to proceed with Phase I clinical trial of GRNOPC1 in spinal cord injury

Geron Corporation announced today that the U.S. Food and Drug Administration (FDA) has notified the company that the clinical hold placed on Geron's Investigational New Drug (IND) application has been lifted and the company's Phase I clinical trial of GRNOPC1 in patients with acute spinal cord injury may proceed.

30 Jul 2010

Partners in ENIAC project announce details of multinational/multidisciplinary program

The partners in a new publicly-funded European research project today announced details of the multinational/multidisciplinary program: 'CSI: Central Nervous System Imaging.' This three-year ENIAC project aims to achieve substantial advances in state-of-the-art medical 3D-imaging platforms by focusing on the diagnosis and therapy of serious diseases of the central nervous system and brain.

30 Jul 2010

ACADIA initiates new pimavanserin Phase III trial for Parkinson's disease psychosis

ACADIA Pharmaceuticals Inc., a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it has initiated a new Phase III trial designed to evaluate the efficacy, tolerability and safety of pimavanserin as a treatment for patients with Parkinson's disease psychosis (PDP).

30 Jul 2010

Michelangelo appears to have hidden image of brainstem, spinal cord in Sistine Chapel's ceiling: Study

Michelangelo, the 16th century master painter and accomplished anatomist, appears to have hidden an image of the brainstem and spinal cord in a depiction of God in the Sistine Chapel's ceiling, a new study by Johns Hopkins researchers reports. These findings by a neurosurgeon and a medical illustrator, published in the May Neurosurgery, may explain long controversial and unusual features of one of the frescoes' figures.

29 Jul 2010

Safeguard Scientifics second-quarter aggregate revenue of partner companies increase 47% to $91.6 million

Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced that aggregate revenue of its partner companies for the three months ended June 30, 2010 was $91.6 million, up 47% from $62.3 million for the same partner companies in the same period of 2009. For the six months ended June 30, 2010, the aggregate partner company revenue was $176.9 million, up 45% from $121.8 million for the same partner companies for the same period of 2009.

29 Jul 2010

Central Nervous System News and Research

OptiNose's bi-directional nasal device delivering fluticasone effective in reducing nasal polyps in CRS patients

AACN endorses new clinical practice guidelines developed by Renal Physicians Association

Trigemina reports positive results from TI-001 Phase IIa clinical trial for Chronic Daily Headache

Georgia Institute receives EUREKA grant to design brain tumor treatment

Omeros net loss for second-quarter 2010 increases to $7.8 million

China Pharma second-quarter revenue increases 22% to $16.6 million

ACADIA second-quarter net loss decreases to $4.3 million

Scientists induce nerve tissue regeneration in patients with spinal cord injury

Need for trained medical professionals to treat medical emergencies in high school athletes

Biovail second-quarter total revenues increase 23% to $238.8 million

Life Technologies, UCSD Moores Cancer Center to use SOLiD 4 technology to study CLL

Vanda second-quarter 2010 revenues decrease by $4.1M

BioClinica second-quarter service revenues increase to $15.7 million

Research shows no link between CCSVI and development of multiple sclerosis

Measuring GAPDH inhibiting antibodies can result in long-term treatment for MS

FDA lifts hold, allows Geron to proceed with Phase I clinical trial of GRNOPC1 in spinal cord injury

Partners in ENIAC project announce details of multinational/multidisciplinary program

ACADIA initiates new pimavanserin Phase III trial for Parkinson's disease psychosis

Michelangelo appears to have hidden image of brainstem, spinal cord in Sistine Chapel's ceiling: Study

Safeguard Scientifics second-quarter aggregate revenue of partner companies increase 47% to $91.6 million

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News